Federal Register / Vol. 87, No. 116 / Thursday, June 16, 2022 / Notices 36337 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Chimeric Adaptor 

Proteins (CAPs) for Use in Cancer 

Immunotherapy Against Solid Tumors 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

U.S. Patents and Patent Applications 

listed in the Supplementary Information 

section of this notice to Preverna, Inc. 

located in California, USA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before July 1, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Suna Gulay French, 

Technology Transfer Manager, 

Telephone: (240) 276–7424; Email: 

suna.gulay@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. United States Provisional Patent 

Application No. 62/819,386, filed March 

15, 2019 and entitled ‘‘Recombinant 

Molecules Containing Linker for 

Activation of T cells and Their Use in 

Immunotherapy’’ [HHS Ref. No. E–210– 

2018–0–US–01]; 

2. PCT Patent Application No. PCT/ 

US2020/022752, filed March 13, 2020 

and entitled ‘‘Chimeric Adaptor and 

Kinase Signaling Proteins and Their Use 

in Immunotherapy’’ [HHS Ref. No. E– 

210–2018–0–PCT–02]; 

3. European Patent Application No. 

20718061.3, filed March 13, 2020 and 

entitled ‘‘Chimeric Adaptor and Kinase 

Signaling Proteins and Their Use in 

Immunotherapy’’ [HHS Ref. No. E–210– 

2018–0–EP–03]; 

4. Chinese Patent Application No. 

202080021582.5, filed March 13, 2020 

and entitled ‘‘Chimeric Adaptor and 

Kinase Signaling Proteins and Their Use 

in Immunotherapy’’ [HHS Ref. No. E– 

210–2018–0–CN–04]; 

5. Hong Kong Patent Application No. 

62022051308.4, filed March 13, 2020 

and entitled ‘‘Chimeric Adaptor and 

Kinase Signaling Proteins and Their Use 

in Immunotherapy’’ [HHS Ref. No. E– 

210–2018–0–HK–05]; and 

6. United States Patent Application 

No. 17/475,810, filed September 15, 

2021 and entitled ‘‘Chimeric Adaptor 

Proteins (CAPs) for Improved T-Cell 

Immunotherapy’’ [HHS Ref. No. E–210– 

2018–1–US–01]. 

(and U.S. and foreign patent 

applications claiming priority to the 

aforementioned applications). 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to: 

‘‘Development and commercialization of 

T cell and Natural Killer cell therapy 

products engineered by lentiviral 

transduction and/or lipid nanoparticle 

encapsulated mRNA transfection to 

express the Chimeric Adaptor Proteins 

claimed in the prospective licensed 

patent rights, for the treatment of solid 

tumors.’’ 

This technology discloses Chimeric 

Adaptor Proteins (CAPs) for use in 

cancer immunotherapy. While similar to 

chimeric antigen receptors (CARs) in 

their content and mechanism of action, 

CAPs do not comprise a T cell receptor 

(TCR) domain and do not rely on TCR 

activation to stimulate the immune 

response. The inventors have instead 

found that adaptor molecules such as 

the linker for activation of T cells (LAT) 

are sufficient to form a distinct signaling 

complex and cause full immune cell 

activation. The functional features of 

CAPs may provide an advantage in 

immunotherapy, particularly against 

solid tumors. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 10, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–12954 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Development of 

microbiome-related approaches for 

diagnosis/mitigation/treatment of radiation 

injuries (U01 clinical trial not allowed). 

Date: July 11–12, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G41, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Kelly L. Hudspeth, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G41 Rockville, MD 

20852, 240–669–5067, kelly.hudspeth@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 


khammond on DSKJM1Z7X2PROD with NOTICES
36338 Federal Register / Vol. 87, No. 116 / Thursday, June 16, 2022 / Notices 

Dated: June 10, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12952 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NST–1 Overflow Review. 

Date: June 29, 2022. 

Time: 4:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: William C. Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS, NIH NSC, 6001 Executive Boulevard, 

Suite 3204, MSC, 9529 Rockville, MD 20852, 

301–496–0660, benzingw@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: June 10, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12949 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Integrated 

Multi-Component Projects in Aging Research. 

Date: July 7, 2022. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Isis S. Mikhail, MD, MPH, 

DRPH, National Institute on Aging Gateway 

Building, 7201 Wisconsin Avenue, Suite 

2C212, Bethesda, MD 20892, 301–402–7704, 

mikhaili@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: June 10, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12926 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–NS– 

22–037: HEAL Initiative: Advancing Health 

Equity in Pain and Comorbidities. 

Date: July 19, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Randolph Christopher 

Capps, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 1009J, Bethesda, MD 20892, (301) 435– 

1042, cappsrac@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 10, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12951 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Peter Tung at 240–669–5483, or 

peter.tung@nih.gov. Licensing 

information and copies of the patent 

applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD, 20852; tel. 

301–496–2644. A signed Confidential 


khammond on DSKJM1Z7X2PROD with NOTICES